ESR1 and breast carcinoma: The results revealed that in breast cancer PDOs, HER-2 and estrogen receptor (ER) exhibited strong immunoreactivity, whereas progesterone receptor (PR) expression was lower, consistent with the phenotype of primary breast cancer (Figure 2a).